Department of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Second College of Clinical Medicine, Nanchang University, Nanchang, Jiangxi Province, People’s Republic of China.
Aging (Albany NY). 2023 Apr 8;15(7):2734-2771. doi: 10.18632/aging.204645.
Hepatocellular carcinoma represents the most common primary malignancy of all liver cancer types and its prognosis is usually unsatisfactory. TSEN54 encodes a protein constituting a subunit of the tRNA splicing endonuclease heterotetramer. Previous researches concentrated on the contribution of TSEN54 in pontocerebellar hypoplasia, but no studies have yet reported its role in HCC.
TIMER, HCCDB, GEPIA, HPA, UALCAN, MEXPRESS, SMART, TargetScan, RNAinter, miRNet, starBase, Kaplan-Meier Plotter, cBioPortal, LinkedOmics, GSEA, TISCH, TISIDB, GeneMANIA, PDB, GSCALite were applied in this research.
We identified the upregulation of TSEN54 expression in HCC and related it to multiple clinicopathological features. Hypomethylation of TSEN54 was closely associated with its high expression. HCC sufferers who held high TSEN54 expression typically had shorter survival expectations. Enrichment analysis showed the involvement of TSEN54 in the cell cycle and metabolic processes. Afterward, we observed that TSEN54 expression level had a positive relationship to the infiltration level of multiple immune cells and the expression of several chemokines. We additionally identified that TSEN54 was related to the expression level of several immune checkpoints and TSEN54 was linked to several m6A-related regulators.
TSEN54 is a prognostic marker of HCC. TSEN54 could become a prospective candidate for HCC diagnosis and therapy.
肝细胞癌是所有肝癌类型中最常见的原发性恶性肿瘤，其预后通常不理想。TSEN54 编码一种构成 tRNA 剪接内切酶异源四聚体亚基的蛋白质。以前的研究集中在 TSEN54 在桥脑小脑发育不全中的作用，但尚未有研究报道其在 HCC 中的作用。
TIMER、HCCDB、GEPIA、HPA、UALCAN、MEXPRESS、SMART、TargetScan、RNAinter、miRNet、starBase、Kaplan-Meier Plotter、cBioPortal、LinkedOmics、GSEA、TISCH、TISIDB、GeneMANIA、PDB、GSCALite 被应用于本研究中。
我们鉴定出 TSEN54 在 HCC 中的表达上调，并将其与多种临床病理特征相关联。TSEN54 的低甲基化与高表达密切相关。高表达 TSEN54 的 HCC 患者的生存预期通常较短。富集分析表明 TSEN54 参与细胞周期和代谢过程。随后，我们观察到 TSEN54 的表达水平与多种免疫细胞的浸润水平以及几种趋化因子的表达呈正相关。我们还发现，TSEN54 与几种免疫检查点的表达水平相关，并且 TSEN54 与几种 m6A 相关调节剂相关。
TSEN54 是 HCC 的预后标志物。TSEN54 可能成为 HCC 诊断和治疗的有前途的候选物。
